Cargando…

Correction to: Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases

Detalles Bibliográficos
Autores principales:	Tan, Wan-Ling, Ng, Quan Sing, Lim, Cindy, Tan, Eng Huat, Toh, Chee Keong, Ang, Mei-Kim, Kanesvaran, Ravindran, Jain, Amit, Tan, Daniel S. W., Lim, Darren Wan-Teck
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6304773/ https://www.ncbi.nlm.nih.gov/pubmed/30583726 http://dx.doi.org/10.1186/s12885-018-5215-7

Ejemplares similares

Influence of afatinib dose on outcomes of advanced EGFR-mutant NSCLC patients with brain metastases
por: Tan, Wan-Ling, et al.
Publicado: (2018)

A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
por: Lai, Gillianne G.Y., et al.
Publicado: (2022)

Phase I Study of Oral Vinorelbine in Combination with Erlotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) Using Two Different Schedules
por: Sutiman, Natalia, et al.
Publicado: (2016)

Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities
por: Chua, Khi Pin, et al.
Publicado: (2021)

Real world efficacy of osimertinib in second line/beyond in patients with metastatic EGFR+ non-small cell lung cancer and role of paired tumour-plasma T790M testing at tyrosine kinase inhibitor resistance
por: Ma, Jun, et al.
Publicado: (2023)

Impact of Smoking and Brain Metastasis on Outcomes of Advanced EGFR Mutation Lung Adenocarcinoma Patients Treated with First Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
por: Jain, Amit, et al.
Publicado: (2015)

The Issue of Tissue in Molecular Stratification
por: Tan, Min‐Han, et al.
Publicado: (2017)

Real-world experience of first-line afatinib in patients with EGFR-mutant advanced NSCLC: a multicenter observational study
por: Ho, Gwo-Fuang, et al.
Publicado: (2019)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting
por: Park, Keunchil, et al.
Publicado: (2019)

Association of clinical factors with survival outcomes in laryngeal squamous cell carcinoma (LSCC)
por: Fong, Pei Yuan, et al.
Publicado: (2019)

Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC
por: Kulkarni, Amit A, et al.
Publicado: (2022)

Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor–Positive Non–Small Cell Lung Cancer
por: Saw, Stephanie P. L., et al.
Publicado: (2021)

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression
por: Schuler, Martin, et al.
Publicado: (2019)

Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing
por: Nahar, Rahul, et al.
Publicado: (2018)

Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
por: Jiang, Yingying, et al.
Publicado: (2023)

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
por: Tan, Ping-Tee, et al.
Publicado: (2018)

Hydration effects on the efficacy of the Epidermal growth factor receptor kinase inhibitor afatinib
por: Kannan, Srinivasaraghavan, et al.
Publicado: (2017)

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
por: Harvey, R Donald, et al.
Publicado: (2020)

Afatinib as a Potential Therapeutic Option for Patients With NSCLC With EGFR G724S
por: Wei, Yang, et al.
Publicado: (2021)

Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer
por: Lee, Ning-Yuan, et al.
Publicado: (2023)

Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer
por: Lee, Ning-Yuan, et al.
Publicado: (2023)

Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR ‐mutated NSCLC treated with afatinib
por: Wu, Chen‐Te, et al.
Publicado: (2023)

Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases
por: Ye, Qiuyue, et al.
Publicado: (2023)

Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
por: Yamamoto, Nobuyuki, et al.
Publicado: (2019)

Bisphosphonates enhance antitumor effect of EGFR-TKIs in patients with advanced EGFR mutant NSCLC and bone metastases
por: Zhang, Guowei, et al.
Publicado: (2017)

Phase 1b Trial of Ficlatuzumab, a Humanized Hepatocyte Growth Factor Inhibitory Monoclonal Antibody, in Combination With Gefitinib in Asian Patients With NSCLC
por: Tan, Eng‐Huat, et al.
Publicado: (2018)

Response to Afatinib in a Patient with NSCLC Harboring Novel EGFR Exon 20 Insertion Mutations
por: Lin, Ling, et al.
Publicado: (2020)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial
por: Kobayashi, Nobuaki, et al.
Publicado: (2020)

Lipidomic Profiling of Lung Pleural Effusion Identifies Unique Metabotype for EGFR Mutants in Non-Small Cell Lung Cancer
por: Ho, Ying Swan, et al.
Publicado: (2016)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC
por: Goh, Kah Yee, et al.
Publicado: (2023)

A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China
por: Tu, Hai-Yan, et al.
Publicado: (2022)

Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
por: Ribeiro Gomes, Jéssica, et al.
Publicado: (2015)

Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review
por: Marampon, Francesco, et al.
Publicado: (2022)

Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia
por: How, Soon Hin, et al.
Publicado: (2022)

HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma
por: Toh, Yi Long, et al.
Publicado: (2020)

Association of ABCB1 and FLT3 Polymorphisms with Toxicities and Survival in Asian Patients Receiving Sunitinib for Renal Cell Carcinoma
por: Chu, Ying-Hsia, et al.
Publicado: (2015)

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors
por: Park, Keunchil, et al.
Publicado: (2021)

Letter to the editor concerning first-line therapy with afatinib – an irreversible EGFR TKI and overall survival of NSCLC patients with EGFR gene mutations
por: Krawczyk, Paweł, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t52k2o1ko70jcnqb78p6c192l6